Vascular disrupting agent arsenic trioxide enhances thermoradiotherapy of solid tumors

Robert J. Griffin, Brent W. Williams, Nathan A. Koonce, John C. Bischof, Chang W. Song, Rajalakshmi Asur, Meenakshi Upreti

Research output: Contribution to journalArticlepeer-review

12 Scopus citations


Our previous studies demonstrated arsenic trioxide- (ATO-) induced selective tumor vascular disruption and augmentation of thermal or radiotherapy effect against solid tumors. These results suggested that a trimodality approach of radiation, ATO, and local hyperthermia may have potent therapeutic efficacy against solid tumors. Here, we report the antitumor effect of hypofractionated radiation followed by ATO administration and local 42.5°C hyperthermia and the effects of cisplatin and thermoradiotherapy. We found that the therapeutic efficacy of ATO-based thermoradiotherapy was equal or greater than that of cisplatin-based thermoradiotherapy, and marked evidence of in vivo apoptosis and tumor necrosis were observed in ATO-treated tumors. We conclude that ATO-based thermoradiotherapy is a powerful means to control tumor growth by using vascular disruption to augment the effects of thermal and radiation therapy.

Original languageEnglish (US)
Article number934918
JournalJournal of Oncology
StatePublished - 2012


Dive into the research topics of 'Vascular disrupting agent arsenic trioxide enhances thermoradiotherapy of solid tumors'. Together they form a unique fingerprint.

Cite this